Navigation Links
Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
Date:2/13/2013

LA JOLLA, Calif., Feb. 13, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the fourth quarter and year ended December 31, 2012 on Wednesday, February 20, 2013, after the U.S. financial markets close.

Regulus will host a conference call and webcast on Wednesday, February 20, 2013 at 5:00 pm Eastern Standard Time to discuss its fourth quarter and year-end 2012 financial results, recent company highlights and its expectations for 2013. A live webcast of the call will be available online at www.regulusrx.com.  To access the telephone replay of the call, dial (855) 859-2056 (domestic) or (404) 537-3406 (international), passcode 10388595. The webcast and telephone replay will be archived on the company's website for two weeks following the call. 

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals and Isis Pharmaceuticals. Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus to Present at Two Upcoming Investor Conferences
2. Regulus Appoints Mark G. Foletta to its Board of Directors
3. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
4. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
5. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
6. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
7. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
8. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
9. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
10. CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
11. Xenon Announces Appointment of EVP, Research & Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... , May 22, 2017  As the specialty ... whole continue to make the revolutionary shift from ... important for ensuring positive patient outcomes and shaping ... are shifting focus away from clinical trials and ... of long-term specialty drug therapy utilization in precise ...
(Date:5/15/2017)... May 15, 2017  Amy Baxter MD, chief executive ... in noninvasive pain relief, was awarded a 2017 Top ... Baxter was recognized at the MM&M Top 40 Healthcare ... City on May 10, 2017. The dinner ... industry go "beyond the pill."  "Innovation goes ...
(Date:5/11/2017)... May 11, 2017  Thornhill Research Inc. ( ... awarded an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract ... Canadian Commercial Corporation (CCC) ( Ottawa, Ontario, ... to administer general anesthesia to patients requiring emergency ... "The US Marine Corps have been a longtime ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... , ... From May 21-23, hearing healthcare professionals gained a competitive edge with ... Marriott Syracuse Downtown Hotel in Syracuse, New York. , As EarQ’s technology partner, ... providers to help them stay ahead in the industry. At the event, EarQ members ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... CEO 2017 on May 30th and 31st at The Four Seasons Hotel Boston. ... executives in the life sciences, offering exclusive access to key decision makers who ...
(Date:5/26/2017)... , ... May 26, 2017 , ... A new analysis ... with the healthiest seniors are located in the Midwest. With the average cost of ... more people are concerned with both the quality and affordability of where they live. ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original campaign ... crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget to ... fidget toy to the market that was made of superior quality and wouldn’t break ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon ... informational blog post on insurance options. If a Bay Area patient has to search ... time and money. Visiting an in-network provider for a second opinion can ensure a ...
Breaking Medicine News(10 mins):